- Home
- SDGR vs XNCR Comparison
SDGR vs XNCR Comparison
Compare SDGR & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SDGR | XNCR |
|---|---|---|
| Founded | 1990 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.7M | 881.9M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SDGR | XNCR |
|---|---|---|
| Price | $12.46 | $11.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $21.75 | ★ $22.89 |
| AVG Volume (30 Days) | ★ 1.4M | 644.9K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.14 | ★ 65.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,869,000.00 | $125,576,000.00 |
| Revenue This Year | $6.11 | N/A |
| Revenue Next Year | $7.69 | $6.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.29 | 13.65 |
| 52 Week Low | $11.11 | $6.92 |
| 52 Week High | $27.63 | $18.69 |
Technical Indicators
Market Signals| Indicator | SDGR | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 48.51 |
| Support Level | $11.11 | $10.92 |
| Resistance Level | $13.36 | $12.73 |
| Average True Range (ATR) | 0.71 | 0.90 |
| MACD | 0.19 | 0.04 |
| Stochastic Oscillator | 57.92 | 34.18 |
Price Performance
Historical ComparisonAbout SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.